Form 4: Protara Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, sold 21,224 shares of common stock at an average price of $4.53 under a pre-arranged 10b5-1 trading plan.

Summary

• On March 26, 2025, Jacqueline Zummo, the Chief Scientific Operations Officer of Protara Therapeutics, sold 21,224 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan established on December 23, 2024.
• The shares were sold at a weighted average price of $4.53, with individual transactions ranging from $4.41 to $4.69.
• Following the transaction, Zummo directly owns 98,861 shares of Protara Therapeutics.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote, upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice among corporate executives to avoid accusations of insider trading. It doesn't necessarily reflect a change in the executive's confidence in the company.

Key Dates

Keywords

Form 4, Protara Therapeutics, TARA, Insider Trading, Jacqueline Zummo, 10b5-1 Trading Plan, Stock Sale, Chief Scientific Operations Officer